ESMO 2022 | How effective are ADCs in treating metastatic urothelial cancer?

Andrea Necchi, MD, Istituto Nazionale dei Tumori, Milan, Italy, comments on the efficacy and toxicity of antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer. Trials such as the Phase I/II EV-103 trial (NCT03288545) of enfortumab vedotin, an ADC, with pembrolizumab in patients with urothelial cancer have demonstrated the promising efficacy of ADCs in this group of patients. Prof. Necchi additionally highlights the need to educate clinicians on the safety profile and potential adverse events that may arise from taking ADCs. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.